The HINT1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population derived from the human hepatocellular carcinoma line SK-HEP-1. This knockout model is engineered to ablate the expression of HINT1, a nucleotide phosphoramidase with established tumor-suppressive functions. The polyclonal format preserves the genetic heterogeneity inherent to cell populations post-editing, ensuring that the pool reflects a spectrum of editing outcomes while uniformly eliminating functional HINT1 protein. Researchers can leverage this system to dissect HINT1-dependent signaling mechanisms in a hepatic tumor context without the constraints of clonal selection. The product is supplied as a cryopreserved vial of viable cells, ready for immediate culture and downstream applications, and is validated for target-gene disruption via standard molecular assays.
The host cell line, SK-HEP-1, is a well-characterized human liver adenocarcinoma cell line frequently employed as a model for hepatocellular carcinoma. Originally isolated from the ascites of a patient with liver cancer, SK-HEP-1 cells exhibit tumorigenic properties and retain key features of hepatic malignancy, including abnormal proliferation, migration, and altered signaling pathway activity. The adherent epithelial morphology and robust growth characteristics make this line suitable for a wide range of in vitro assays. In the context of HINT1 knockout, the SK-HEP-1 background provides a relevant cellular environment to study the tumor-suppressor role of HINT1, as loss of HINT1 expression has been implicated in hepatocellular carcinoma progression. The cell line??s endogenous signaling landscape, including active Wnt/??-catenin and NF-??B pathways, offers a physiologically pertinent setting for examining HINT1-mediated regulatory networks.
HINT1 functions as a nucleotide phosphoramidase that exerts tumor-suppressive effects primarily by enhancing p53-dependent apoptosis and antagonizing Wnt/??-catenin signaling. Mechanistically, HINT1 interacts with ??-catenin and the transcription factor TCF4 to disrupt the ??-catenin/TCF4 complex, thereby repressing Wnt target gene transcription. It is also regulated upstream by p53 and ER stress, while downstream it modulates factors including MITF, USF2, caspase-3, and c-Myc. Additionally, HINT1 interacts with MITF, USF2, PCAF, and TRPV1, and forms complexes that influence both apoptosis and pain perception pathways. The protein participates in a broader network involving I??B??, SMAD2/3, and PKC, linking it to NF-??B and TGF-?? signaling. Through these interactions, HINT1 orchestrates cross-talk between cell death, transcription, and developmental pathways, making its disruption consequential for oncogenic reprogramming.
In the hepatocellular carcinoma setting, HINT1 knockout is particularly significant given the gene??s putative role as a liver tumor suppressor. SK-HEP-1 cells harboring disrupted HINT1 are expected to exhibit enhanced Wnt/??-catenin activity, reduced p53-mediated apoptosis, and altered transcriptional regulation by MITF and USF2, mirroring aggressive tumor phenotypes. This model thus enables the investigation of oncogenic mechanisms driven by HINT1 loss, such as unchecked proliferation and evasion of cell death. Moreover, the interplay between HINT1 and pathways dysregulated in hepatic malignancies??including TGF-??, NF-??B, and Wnt signaling??can be systematically probed. Researchers may assess how HINT1 ablation affects the cellular response to chemotherapeutic agents or influences epithelial-mesenchymal transition, providing insights into drug resistance and metastasis.
The HINT1 Knockout SK-HEP-1 Polyclonal Cells are suited for a diverse array of research applications, including liver cancer biology, tumor-suppressor network analysis, apoptosis signaling, and Wnt pathway interrogation. Typical experimental workflows include Western blotting and RT-qPCR to confirm HINT1 disruption and downstream target expression, ??-catenin/TCF luciferase reporter assays to measure Wnt transcriptional activity, and Annexin V staining for apoptosis quantification. Co-immunoprecipitation can validate HINT1 interaction partners such as ??-catenin or MITF, while wound healing migration assays assess metastatic potential. Drug sensitivity screens may be performed using cell viability readouts, and transcriptome-wide changes can be evaluated by RNA-seq. For further information regarding this product, please contact Ascent Research.
